Panel discussion: Is clinical trial exclusion criteria too stringent?

About this session

- How is the industry approaching diversity and what should the primary focus be?

- Increasing accessibility to trials whilst simultaneously maintaining an appropriate level of patient safety

- Assessing the link between restrictive eligibility criteria and rates of serious adverse events to make informed decisions on expanding exclusion conditions

- Alternative solutions to improve patient numbers amidst pressures to hit recruitment milestones

- How have increased pressures of patient recruitment lead to the questioning of traditional enrollment methods?

Chair: Cathy Scharf, Patient Advocate, Patient Advocates of the East Bay

Speakers

• 

  Jad Adaimi

  Executive Director - Global Regulatory Affairs · Ultragenyx

  Panelist

• 

  Marla Williams

  Associate R&D Strategic Outsourcing Director · Exelixis

  Panelist

• 

  Nisha Trivedi

  Rare Disease Patient Advocate

  Panelist

• 

  Meghan McKenzie

  Patient Inclusion and Health Equity, Chief Diversity Office · Genentech

  Panelist

• 

  Cathy Scharf

  Patient Advocate · Patient Advocates of the East Bay

  Panelist